Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer
NCT ID: NCT01032746
Last Updated: 2013-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized clinical trial is studying personal electronic health records to see how well they work in improving screening rates for colorectal cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To assess whether screening rates for colorectal cancer (CRC) can be substantially increased among adults in primary care through the use of a personal electronic health record that provides a link to a validated web-based tool to estimate an individual's risk of CRC and electronic scheduling of CRC screening exams.
OUTLINE: This is a multicenter study. Participants are stratified according to participating Harvard Vanguard Medical Associates (HVMA) center. Participants are randomized to 1 of 2 arms.
* Intervention arm: Participants receive an electronic message within their MyHealth account on behalf of their primary care physician providing a link to a web-based tool to allow them to assess their personal risk of colorectal cancer (CRC). The tool provides an estimate of an individual's personal risk of developing different types of cancer over the next 10 years relative to others of the same age and sex. The tool also recommends steps that individuals can take to reduce their risk. The tool includes questions about family history; prior screening tests; dietary habits (red meat, fruits, and vegetables); weight and height; and use of folate, aspirin, estrogen therapy, alcohol, and tobacco. In addition, the electronic message provides information regarding options for CRC screening, emphasizing colonoscopy every 10 years per the current HVMA guidelines, followed by the secondary recommendation of annual fecal occult blood testing. Detailed information is provided in the form of a link to online educational materials. Participants may request either colonoscopy or fecal occult blood testing by responding to the electronic message and indicating their preference. Participants who request colonoscopy are contacted by the gastroenterology department to proceed with CRC screening; participants who request fecal occult blood testing will receive a stool card test kit in the mail from their primary care physician.
* Control arm: Participants receive no intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SCREENING
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
educational intervention
internet-based intervention
evaluation of cancer risk factors
fecal occult blood test
screening colonoscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Overdue for colorectal cancer screening (identified using automated extracts from the electronic medical record), as defined by the following criteria:
* No fecal occult blood test within the past 12 months
* No flexible sigmoidoscopy within the past 5 years
* No colonoscopy within the past 10 years
* Receiving primary care at a Harvard Vanguard Medical Associates (HVMA) center
* Registered to use the HVMA patient portal (MyHealth) AND has an active MyHealth account
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Harvard University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Harvard Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Ayanian, MD, MPP
Role: STUDY_CHAIR
Harvard Medical School (HMS and HSDM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Harvard Medical School
Boston, Massachusetts, United States
Harvard Vanguard Medical Associates - Kenmore
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
John Ayanian, MD, MPP
Role: primary
Thomas D. Sequist, MD, MPH
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Sequist TD, Zaslavsky AM, Colditz GA, Ayanian JZ. Electronic patient messages to promote colorectal cancer screening: a randomized controlled trial. Arch Intern Med. 2011 Apr 11;171(7):636-41. doi: 10.1001/archinternmed.2010.467. Epub 2010 Dec 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMS-11960
Identifier Type: -
Identifier Source: secondary_id
CDR0000661288
Identifier Type: -
Identifier Source: org_study_id